SCHEMBL27089673

SCHEMBL27089673

C=C1NC2CSC(CCCCC(=O)NCCOCCOCCOCCOCCC(=O)N3CCN(c4ccc(C(C)C)cc4)CC3)C2N1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TXK P42681 1/20 0.48
JAK3 P52333 1/20 0.48
BTK Q06187 1/20 0.48
CA12 O43570 1/20 0.48
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48
CA9 Q16790 1/20 0.48
FOLH1 Q04609 5/20 0.47
NOXO1 Q8NFA2 1/20 0.47
EP300 Q09472 1/20 0.47
PRSS1 P07477 3/20 0.46
PRSS2 P07478 3/20 0.46
PRSS3 P35030 3/20 0.46
TPSAB1 Q15661 3/20 0.46
F2 P00734 2/20 0.46
PLG P00747 2/20 0.46
PKM P14618 2/20 0.46
MAP3K7 O43318 1/20 0.46
HSP90AB1 P08238 1/20 0.45
MAPK3 P27361 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23365946 0.92 CA12 (0.58) TXKJAK3BTKCA12CA1
SCHEMBL27089672 0.86 PRSS1 (0.49) TXKJAK3BTKFOLH1NOXO1
SCHEMBL20161403 0.84 CA12 (0.60) TXKJAK3BTKCA12CA1
SCHEMBL23365942 0.82 CA12 (0.58) TXKJAK3BTKCA12CA1
SCHEMBL26553927 0.79 PRSS1 (0.56) CA12CA1CA2CA9FOLH1
SCHEMBL26554090 0.78 PRSS1 (0.59) CA12CA1CA2CA9FOLH1
SCHEMBL26553921 0.78 PRSS1 (0.59) CA12CA1CA2CA9FOLH1
SCHEMBL23365916 0.78 F2 (0.60) FOLH1NOXO1PRSS1PRSS2PRSS3
SCHEMBL20161540 0.77 F2 (0.62) CA12CA1CA2CA9FOLH1
SCHEMBL12028695 0.76 PRSS1 (0.62) CA12CA1CA2CA9FOLH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11897874-B2 Compounds and methods for modulating Interleukin-2-inducible T-cell kinase CORVUS PHARMACEUTICALS, INC. (US) 2024-02-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11897874-B2 Compounds and methods for modulating Interleukin-2-inducible T-cell kinase IL2, NFATC1, IL2RA TXK 201/4885JAK3 341/4885BTK 398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.